Samsung Bioepis, Merck Launch Remicade Biosimilar Early, Following SCOTUS Decision

Drug Industry Daily
A A
Samsung Bioepis and Merck announced the U.S. launch of Renflexis (infliximab-abda), a biosimilar of Janssen’s Remicade (infliximab).

To View This Article:

Login

Subscribe To Drug Industry Daily